Company: BIAF
Filing Date: 2025-02-27
Form Type: 8-K
Source: 0001493152-25-008471
Chunk: 3

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-02-27
Form: 8-K
Item: Item 1.01
Chunk 3
---
giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of such warrants. However, any
holder may increase or decrease such percentage, provided that any increase will not be effective until the 61st day after such election.

In
the event of a Fundamental Transaction (as such term is defined in the New Warrants), then the successor entity will succeed to, and
be substituted for the Company, and may exercise every right and power that the Company may exercise and will assume all of its obligations
under the New Warrants with the same effect as if such successor entity had been named in the warrant itself. If holders of Common Stock
are given a choice as to the securities, cash or property to be received in a Fundamental Transaction, then the holder shall be given
the same choice as to the consideration it receives upon any exercise of the New Warrants following such Fundamental Transaction. In
addition, the successor entity, at the request of holders of New Warrants, will be obligated to purchase any unexercised portion of the
New Warrants in accordance with the terms thereof. Notwithstanding the foregoing, in the event of a Fundamental Transaction, the holders
of the New Warrants have the right to require the Company or a successor entity to redeem the New Warrants for cash in the amount of
the Black Scholes Value (as defined in the New Warrants) of the unexercised portion of the New Warrants concurrently with or within 30
days following the consummation of a Fundamental Transaction. However, in the event of a Fundamental Transaction which is not in the
Company’s control, including a Fundamental Transaction not approved by the Company’s board of directors, the holders of the
New Warrants will only be entitled to receive from the Company or its successor entity the same type or form of consideration (and in
the same proportion), at the Black Scholes Value of the unexercised portion of the New Warrant that is being offered and paid to the
holders of Common Stock in connection with the Fundamental Transaction, whether that consideration is in the form of cash, stock or any
combination of cash and stock, or whether the holders of Common Stock are given the choice to receive alternative forms of consideration
in connection with the Fundamental Transaction.

Except
as otherwise provided in the New Warrants or by virtue of such holder’s ownership of shares of Common Stock, the holder of the
New Warrants will not have the rights or privileges of a holder of